

Date of preparation:

21 August 2026

Issuer's abbreviated name:

SYNEKTIK SA

Current report:

40/2026 ESPI

Subject:

Information on the conclusion of a significant sales agreement under the e-Zdrowie KPO project

Legal basis:

Art. 17 sec. 1 MAR – inside information

Body of the report:

Time of publication: 5:46 a.m.

The Management Board of Synektik SA (Company) reports that a Company has concluded a significant agreement with Centrum e-Zdrowia [E-Health Centre], with its registered office at: ul. Stanisława Dubois 5A, 00-184 Warsaw (Contracting Authority) and a Consortium formed by Synektik SA as the leading member and Carebot s.r.o., with its registered office at: Libušina 49/3, Vyšehrad, 128 00 Prague 2, Czech Republic, as a member (Consortium).

This agreement pertains to the delivery, implementation and maintainance of artificial intelligence (AI) models for the breast cancer lesions detection (mammography), which analyze imaging data (DICOM) and provide results, together with integration with the Intelligent Services Platform (PUI), as well as the provision of workstation training and user support regarding the use of the supplied SI models, as part of order IV of the e-Zdrowie KPO project.

This agreement was concluded as a result of a public tender proceeding conducted in the form of an unlimited tender for the maximum net amount of PLN 10,970,761.00.

The agreement will be completed by 20 September 2026. The guarantee period for the delivery of SI models is 5 years from the date of signing the final acceptance protocol. The other clauses of this agreement do not deviate from the standards generally used in agreements of this type.

The signing of this agreement has been deemed to be significant by the Management Board of Synektik SA since its maximum net value exceeds 5% of the equity of the Synektik Group disclosed in the last periodic report, meaning that it surpasses the level prescribed internally in the Company in its individual reporting standards. The proceeds generated by the project may affect the sales results in the 2025 financial year.

Persons representing the Issuer:

Cezary Kozanecki – President of the
Management Board